Corteva (NYSE:CTVA) Price Target Raised to $80.00

Corteva (NYSE:CTVA) had its target price hoisted by stock analysts at CICC Research from $70.00 to $80.00 in a research report issued to clients and investors on Wednesday,MarketScreener reports. The brokerage presently has an “outperform” rating on the stock. CICC Research’s price objective would indicate a potential upside of 5.84% from the company’s current price.

A number of other analysts have also recently weighed in on CTVA. BNP Paribas Exane increased their price objective on shares of Corteva from $70.00 to $72.00 and gave the stock a “neutral” rating in a report on Monday, November 17th. Royal Bank Of Canada upped their target price on shares of Corteva from $80.00 to $89.00 and gave the stock an “outperform” rating in a research report on Thursday, February 5th. Deutsche Bank Aktiengesellschaft lifted their price target on Corteva from $85.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, February 5th. Wall Street Zen lowered Corteva from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Finally, Argus upgraded Corteva to a “strong-buy” rating in a research report on Friday, January 16th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.20.

Corteva Stock Performance

Shares of NYSE CTVA opened at $75.59 on Wednesday. The company has a quick ratio of 0.96, a current ratio of 1.43 and a debt-to-equity ratio of 0.07. The firm’s 50-day moving average price is $69.34 and its two-hundred day moving average price is $68.41. Corteva has a 52-week low of $53.40 and a 52-week high of $77.41. The stock has a market capitalization of $51.08 billion, a P/E ratio of 47.88, a P/E/G ratio of 2.53 and a beta of 0.75.

Corteva (NYSE:CTVA) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $0.22 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.22. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The business had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $4.23 billion. During the same period in the prior year, the firm earned $0.32 EPS. The business’s quarterly revenue was down 1.7% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, sell-side analysts forecast that Corteva will post 2.96 earnings per share for the current year.

Institutional Trading of Corteva

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Andra AP fonden boosted its holdings in shares of Corteva by 36.2% in the fourth quarter. Andra AP fonden now owns 303,390 shares of the company’s stock worth $20,336,000 after buying an additional 80,690 shares during the period. Aviva PLC lifted its position in shares of Corteva by 1.5% in the 4th quarter. Aviva PLC now owns 545,664 shares of the company’s stock valued at $36,576,000 after acquiring an additional 8,050 shares in the last quarter. Qtron Investments LLC acquired a new position in Corteva in the 4th quarter worth approximately $1,108,000. Meiji Yasuda America Inc purchased a new position in Corteva during the 4th quarter worth approximately $3,821,000. Finally, Nuveen LLC raised its stake in Corteva by 0.5% during the 4th quarter. Nuveen LLC now owns 2,059,353 shares of the company’s stock valued at $138,038,000 after purchasing an additional 10,014 shares during the period. Institutional investors and hedge funds own 81.54% of the company’s stock.

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.